Sarepta Therapeutics Shares Rally Ahead of Three-Year Data Reveal for ELEVIDYS in Duchenne Muscular Dystrophy
Sarepta Therapeutics Inc experienced a significant 11% stock gain following its announcement to present three-year topline findings from the Phase 3 EMBARK trial of ELEVIDYS. This gene therapy targets ambulatory children with Duchenne muscular dystrophy (DMD), aiming to demonstrate sustained functional benefits. The upcoming data presentation is sc…